FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2475561659> ?p ?o ?g. }

• W2475561659 endingPage "2019" @default.
• W2475561659 startingPage "2019" @default.
• W2475561659 abstract "Abstract Introduction With routine use of autologous stem cell transplantation (ASCT) and novel agents, survival of patients with multiple myeloma (MM) has improved in recent years. Yet, MM remains incurable and long-term survivors (LTS) of ≥10 years from diagnosis remain uncommon. This study aims to identify patient, disease and treatment characteristics of MM LTS, with particular interest in the effect of novel therapies. Methods A retrospective analysis was conducted of MM patients diagnosed between 1998 and 2002 and treated at Princess Margaret Cancer Centre, a tertiary care institution. LTS were identified by survival of ≥10 years from diagnosis and were compared with patients diagnosed and followed contemporaneously at our institution with survival <10 years from diagnosis. Candidate predictor variables were identified using univariate and multivariate logistic regression analysis; a p value <0.05 was considered statistically significant. Results Seventy-five patients were identified as LTS, with a control group of 119 patients with survival <10 years. The median survival for all patients was 7.3 years (range 0.6-14.5 years). Comparison of patient, disease and treatment characteristics between groups are detailed in Table 1. Patient and disease characteristics: At diagnosis, LTS were younger (p = 0.0005) and at earlier ISS stage (p = 0.02) than non-LTS. At diagnosis, LTS had a higher baseline mean hemoglobin level (p = 0.02) and platelet count (p = 0.003), and less frequently had lytic bone lesions (p = 0.03), consistent with earlier stage at diagnosis. There were no significant differences in baseline mean leukocyte count, serum calcium and creatinine. Cytogenetics were not routinely performed during this time period. Treatment characteristics: Of the LTS, 95% received an ASCT, as compared to 86% of non-LTS (p = 0.77). Median age at transplant was younger in the LTS (p = 0.003). LTS experienced a longer time from transplant to disease progression (TTP) than non-LTS (p < 0.0001) despite achieving similar rates of complete response (CR) and very good partial response (VGPR). Exposure to novel agents was common in both the LTS and control groups (73% vs. 82%, p = 0.24). Length of exposure to thalidomide (p = 0.01) and lenalidomide (p = 0.002) was greater in LTS, leading to higher quality responses and longer TTP with both agents (p < 0.0001 and p = 0.002, respectively). Similarly, bortezomib exposure was longer in the LTS (p = 0.02) with a longer TTP over that achieved in non-LTS (p = 0.008), although the quality of response was not significantly different. In a multivariate analysis, a longer TTP after ASCT (OR = 1.004; 95% CI 1.002-1.006, p = 0.0008), thalidomide (OR = 34; 95% CI 1.7-690.6; p = 0.023) and bortezomib (OR = 28.2; 95% CI 3.5-228; p = 0.002) treatment, though not after lenalidomide, were independently predictive of LTS. Table 1. Comparison of characteristics between LTS and non-LTS Disease characteristics LTS (n=75) Non-LTS (n=119) p -value Age (y) 53.2 59.1 0.0005 ISS stage I 66 43 0.02 II 20 33 III 14 24 Hemoglobin (g/L) 109 102 0.03 Leukocytes (x 109/L) 5.97 6.29 0.45 Platelets (x 109/L) 255 218 0.003 Calcium (mmol/L) 2.41 2.46 0.39 Creatinine (umol/L) 107.5 148.6 0.16 Presence of lytic lesions (%) 55 70 0.03 Treatment characteristics Autologous stem cell transplant Age (median, years) 53.3 59.4 0.003 Response (CR or VGPR, %) 47 44 0.62 TTP (median, months) 59 19.9 0.001 Thalidomide Age (median, years) 11.4 8.2 0.01 Response (CR or VGPR, %) 40 23 0.02 TTP (median, months) 32.4 9.6 <0.0001 Lenalidomide Age (median, years) 23.2 8.1 0.002 Response (CR or VGPR, %) 56 35 0.04 TTP (median, months) 24 10.8 0.002 Bortezomib Age (median, years) 6.8 3.3 0.02 Response (CR or VGPR, %) 40 28 0.24 TTP (median, months) 18 6 0.008 Conclusion LTS with MM received prolonged therapy and achieved higher quality responses to both transplant and novel agents. Our analysis suggests that LTS have baseline characteristics (age, early-stage disease, greater marrow reserve) that may enable them to tolerate more intensive or prolonged therapy. However, it is possible that LTS have disease more indolent or sensitive to therapeutic interventions. The retrospective nature of the study limits our ability to further characterize this. Regardless, these data suggest that the practice of continued exposure to novel agents may contribute to long-term survival in MM. Disclosures Reece: Otsuka: Honoraria, Research Funding; Celgene: Consultancy, Honoraria, Research Funding; Janssen: Consultancy, Honoraria, Research Funding; Millennium: Honoraria, Research Funding; Merck: Research Funding; BMS: Research Funding; Novartis: Honoraria, Research Funding; Amgen: Honoraria. Trudel:Celgene: Honoraria; Novartis: Honoraria; Glaxo Smith Kline: Honoraria, Research Funding; Oncoethix: Research Funding. Kukreti:Celgene: Consultancy, Honoraria. Tiedemann:Janssen: Honoraria. Chen:Celgene: Honoraria; Janssen: Honoraria." @default.
• W2475561659 created "2016-08-23" @default.
• W2475561659 creator A5038365893 @default.
• W2475561659 creator A5043490010 @default.
• W2475561659 creator A5045418082 @default.
• W2475561659 creator A5057189806 @default.
• W2475561659 creator A5067291402 @default.
• W2475561659 creator A5069106696 @default.
• W2475561659 creator A5073300071 @default.
• W2475561659 creator A5073327231 @default.
• W2475561659 creator A5082712392 @default.
• W2475561659 date "2014-12-06" @default.
• W2475561659 modified "2023-10-01" @default.
• W2475561659 title "Patient, Disease and Treatment Characteristics of Long-Term Survivors of Multiple Myeloma" @default.
• W2475561659 doi "https://doi.org/10.1182/blood.v124.21.2019.2019" @default.
• W2475561659 hasPublicationYear "2014" @default.
• W2475561659 type Work @default.
• W2475561659 sameAs 2475561659 @default.
• W2475561659 citedByCount "0" @default.
• W2475561659 crossrefType "journal-article" @default.
• W2475561659 hasAuthorship W2475561659A5038365893 @default.
• W2475561659 hasAuthorship W2475561659A5043490010 @default.
• W2475561659 hasAuthorship W2475561659A5045418082 @default.
• W2475561659 hasAuthorship W2475561659A5057189806 @default.
• W2475561659 hasAuthorship W2475561659A5067291402 @default.
• W2475561659 hasAuthorship W2475561659A5069106696 @default.
• W2475561659 hasAuthorship W2475561659A5073300071 @default.
• W2475561659 hasAuthorship W2475561659A5073327231 @default.
• W2475561659 hasAuthorship W2475561659A5082712392 @default.
• W2475561659 hasConcept C10515644 @default.
• W2475561659 hasConcept C126322002 @default.
• W2475561659 hasConcept C141071460 @default.
• W2475561659 hasConcept C144301174 @default.
• W2475561659 hasConcept C146357865 @default.
• W2475561659 hasConcept C151730666 @default.
• W2475561659 hasConcept C167135981 @default.
• W2475561659 hasConcept C2776364478 @default.
• W2475561659 hasConcept C2779050716 @default.
• W2475561659 hasConcept C2779134260 @default.
• W2475561659 hasConcept C2911091166 @default.
• W2475561659 hasConcept C38180746 @default.
• W2475561659 hasConcept C71924100 @default.
• W2475561659 hasConcept C86803240 @default.
• W2475561659 hasConceptScore W2475561659C10515644 @default.
• W2475561659 hasConceptScore W2475561659C126322002 @default.
• W2475561659 hasConceptScore W2475561659C141071460 @default.
• W2475561659 hasConceptScore W2475561659C144301174 @default.
• W2475561659 hasConceptScore W2475561659C146357865 @default.
• W2475561659 hasConceptScore W2475561659C151730666 @default.
• W2475561659 hasConceptScore W2475561659C167135981 @default.
• W2475561659 hasConceptScore W2475561659C2776364478 @default.
• W2475561659 hasConceptScore W2475561659C2779050716 @default.
• W2475561659 hasConceptScore W2475561659C2779134260 @default.
• W2475561659 hasConceptScore W2475561659C2911091166 @default.
• W2475561659 hasConceptScore W2475561659C38180746 @default.
• W2475561659 hasConceptScore W2475561659C71924100 @default.
• W2475561659 hasConceptScore W2475561659C86803240 @default.
• W2475561659 hasIssue "21" @default.
• W2475561659 hasLocation W24755616591 @default.
• W2475561659 hasOpenAccess W2475561659 @default.
• W2475561659 hasPrimaryLocation W24755616591 @default.
• W2475561659 hasRelatedWork W1863259896 @default.
• W2475561659 hasRelatedWork W1985349485 @default.
• W2475561659 hasRelatedWork W2163263812 @default.
• W2475561659 hasRelatedWork W2367054191 @default.
• W2475561659 hasRelatedWork W2411442805 @default.
• W2475561659 hasRelatedWork W2996494612 @default.
• W2475561659 hasRelatedWork W3140385248 @default.
• W2475561659 hasRelatedWork W3185622540 @default.
• W2475561659 hasRelatedWork W34374534 @default.
• W2475561659 hasRelatedWork W4302009552 @default.
• W2475561659 hasVolume "124" @default.
• W2475561659 isParatext "false" @default.
• W2475561659 isRetracted "false" @default.
• W2475561659 magId "2475561659" @default.
• W2475561659 workType "article" @default.